Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. (CRL) reported total revenue of $4.02 billion for fiscal year 2025, ending December 27, 2025. Despite this revenue level, the company recorded a net loss attributable to common shareholders of $144.3 million, driven by significant impairment charges including $165.0 million in goodwill impairment and $211.0 million in intangible asset impairment. Operating income was $25.2 million, while income before taxes showed a loss of $99.5 million. The company generated strong operating cash flow of $737.6 million, with capital expenditures of $219.2 million. The balance sheet shows total assets of $7.14 billion, with $2.14 billion in long-term debt and $3.17 billion in total equity. Basic and diluted earnings per share were both negative $3.00.

Key Takeaways